Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04839276
Other study ID # THT02
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 1, 2018
Est. completion date February 1, 2019

Study information

Verified date April 2021
Source Fakultas Kedokteran Universitas Indonesia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study tries to see the effect of using a combination of platelet-rich fibrin (PRF) and autologous fat as a filler for injection laryngoplasty procedures to treat unilateral adductor vocal cord paralysis.


Description:

The vocal cord in humans is essential in producing voice used in communication and interaction between us. Vocal cord paralysis causes dysphonia, which interferes with communication, causing disruptions towards social activity and daily activities. One of the managements for vocal cord paralysis is medialisation and augmentation of the vocal cord through injection laryngoplasty. Autologous fat is one of the best fillers that can be used in this procedure, but it is highly absorbable and can be reabsorbed very quickly when injected to body tissues. Platelet Rich Fibrin (PRF) is a biomaterial consisting of growth factors that are thought to improve fat tissue longevity through increase of adipogenesis and angiogenesis. Improvement in fat longevity will improve clinical outcomes after laryngoplasty procedure potentially reducing number of repeated injections needed to achieve satisfactory resolution to vocal cord paralysis. The study evaluates a combination of PRF and autologous microlobular fat compared with autologous microlobular fat alone on laryngoplasty. Subjective evaluation was done by using Voice Handicap Index (VHI-30) questionnaire, while objective evaluation was conducted via computerized acoustic analysis/Multidimensional Voice Program (MDVP), videostroboscopy, and maximum phonation time.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date February 1, 2019
Est. primary completion date June 1, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Subject is diagnosed with unilateral vocal cord paralysis in paramedian position or 3 months lateral onset without movement and mucosal waves of the vocal cords on videostroboscopy. - Willing to give consent Exclusion Criteria: - Has a history of malignancy of the larynx or lung - Subject isn't able to undergo injection laryngoplasty procedure under general anesthesia - Subject with thrombositopenia

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Injection Laryngoplasty with Platelet-rich Fibrin and Autologous Fat
Injection Laryngoplasty with a combination of Platelet-rich Fibrin (PRF) and Autologous Fat. The PRF was made by taking 10 mL of peripheral blood from a healthy donor. Blood is then put inside the tube from the Regen lab kit. The tube was centrifuged with a force of 1,500 g (3000 rpm) for 5 minutes producing platelet-rich plasma (PRP). 4 mL of the aforementioned PRP was transferred to a 10 mL test tube, 1 M CaCl2 was added with a micropipette until final concentration of 25 mM was, reached producing PRF. Autologous fat harvested from the patient's abdomen was then mixed with the PRF solution to create the filler for injection laryngoplasty procedures. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
Procedure:
Injection Laryngoplasty with Autologous Fat
Injection Laryngoplasty with autologous microlobular fat harvested from the patient's abdominal fat. Lidocaine was infiltrated under the umbilicus and then an incision was made in the area followed by fat removal using scissors. The fat was cleaned with 0.9% NaCl solution and then sheared into microlobular form. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.

Locations

Country Name City State
Indonesia Fakultas Kedokteran Universitas Indonesia Jakarta Pusat DKI Jakarta

Sponsors (1)

Lead Sponsor Collaborator
Fakultas Kedokteran Universitas Indonesia

Country where clinical trial is conducted

Indonesia, 

References & Publications (6)

Graboyes EM, Bradley JP, Meyers BF, Nussenbaum B. Efficacy and safety of acute injection laryngoplasty for vocal cord paralysis following thoracic surgery. Laryngoscope. 2011 Nov;121(11):2406-10. doi: 10.1002/lary.22178. Epub 2011 Oct 12. — View Citation

Kwon TK, Buckmire R. Injection laryngoplasty for management of unilateral vocal fold paralysis. Curr Opin Otolaryngol Head Neck Surg. 2004 Dec;12(6):538-42. Review. — View Citation

Mattei A, Desuter G, Roux M, Lee BJ, Louges MA, Osipenko E, Sadoughi B, Schneider-Stickler B, Fanous A, Giovanni A. International consensus (ICON) on basic voice assessment for unilateral vocal fold paralysis. Eur Ann Otorhinolaryngol Head Neck Dis. 2018 Feb;135(1S):S11-S15. doi: 10.1016/j.anorl.2017.12.007. Epub 2018 Feb 3. Review. — View Citation

Rubin AD, Sataloff RT. Vocal fold paresis and paralysis. Otolaryngol Clin North Am. 2007 Oct;40(5):1109-31, viii-ix. Review. — View Citation

Seyed Toutounchi SJ, Eydi M, Golzari SE, Ghaffari MR, Parvizian N. Vocal cord paralysis and its etiologies: a prospective study. J Cardiovasc Thorac Res. 2014;6(1):47-50. doi: 10.5681/jcvtr.2014.009. Epub 2014 Mar 4. — View Citation

Stachler RJ, Francis DO, Schwartz SR, Damask CC, Digoy GP, Krouse HJ, McCoy SJ, Ouellette DR, Patel RR, Reavis CCW, Smith LJ, Smith M, Strode SW, Woo P, Nnacheta LC. Clinical Practice Guideline: Hoarseness (Dysphonia) (Update) Executive Summary. Otolaryngol Head Neck Surg. 2018 Mar;158(3):409-426. doi: 10.1177/0194599817751031. Erratum in: Otolaryngol Head Neck Surg. 2018 Aug;159(2):403. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Voice Handicap Index-30 (VHI-30) questionnaire score The Voice Handicap Index Questionnaire-30 (VHI-30) is a subjective examination that can be used to assess the severity of voice disorders and their impact on social life. The VHI-30 categorizes handicaps into mild, moderate, and severe. This study assessed the VHI-30 score as a numerical scale so that the median value for the treatment and control groups can be obtained. The assessment was carried out based on the patient's perception by addressing complaints for each question (0 = never, 1 = almost never, 2 = sometimes, 3 = almost always, 4 = always). Patients with severe voice disorders will achieve a higher VHI-30 score. Interpretation of the total value of the VHI-30 includes mild disability values of 0 - 30; moderate disability of 31 - 60; and a severe disability of 61-120. Changes in VHI-30 score are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Maximum Phonation Time Maximum phonation time describes the quality of the strength of the vocal cords when oscillating. The calculation of the phonation time will represent objective assessment of voice. Changes in maximum phonation time are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Average Fundamental Frequency (F0) The Average Fundamental Frequency (F0) is a parameter in MDVP that represents the number of vocal cord vibration cycles in one second. The mean frequency ranges from 120 Hz for men and 200 Hz for women, but this is also influenced by age, smoking and accent language. The average fundamental frequency reflects the biochemical characteristics of the vocal cords when interacting with the air flow in its path, these biochemical properties are influenced by the structure of the larynx and muscle tone. Changes in F0 are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Jitter and Shimmer Jitter and Shimmer is a parameter in MDVP that represents variations that occur in the basic frequency. Jitter denotes the chaos of sound wave frequency caused by a lack of control over the vibration of the vocal cords. Shimmer shows the chaos of sound wave amplitude which is influenced by decreased resistance of the glottis and presence of mass lesions of the vocal cords, associated with inadequate adduction of the vocal cords and irregularity of the surface of the vocal cords. Presence of jitter and shimmer denotes that there are disruption in phonation quality caused by problems in vocal cords. Changes in jitter and shimmer are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Noise to Harmonic Ratio (NHR) NHR is a parameter in MDVP that represents ratio of non-harmonic and harmonic waves in a certain sound wave period. NHR describes the quality of the amount of noise in the sound. Inadequate closure of the vocal cords and periodic vibrations of the vocal cords cause excessive air flow as it passes through the vocal cords, causing turbulence and noise. Normal and periodic sound signals will have a small NHR, while dysphonia sound signals will have a large NHR value. Changes in NHR are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Voice Turbulence Index (VTI) VTI (Voice Turbulence Index) is a parameter in MDVP that represents the ratio between non-harmonic waves at high frequencies of 2800 - 5800 Hz and harmonic waves at frequencies of 70 - 4500 Hz. This parameter assesses the energy level of high frequency noise and is largely related to the turbulence of sound caused due to loss of adduction motion. This parameter also relates to variations in the frequency or amplitude of sound, where the turbulence of sound occurs due to changes in muscle control. Changes in VTI are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Amplitude Tremor Intensity Index (ATRI) ATRI is a parameter in MDVP that represents the mean ratio of the low frequency amplitude to the total amplitude of the sound being examined. This parameter indicates the stability and strength of the vocal cords during phonation. Changes in ATRI are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Vocal Cord Closure Pattern The closure pattern of the vocal cords is one of the parameters in videostroboscopy. This examination looks at the pattern and medial edge of the vocal cords when closed and insulated. Changes in Vocal Cord Closure Pattern are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Amplitude The amplitude is one of the parameters in videostroboscopy. Amplitude is the amount of horizontal movement of the vocal cords. The magnitude of the amplitude is assessed by dividing the horizontal line into 5 sections from medial to lateral of the vocal cords. Changes in amplitude are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Mucosal Waves The mucosal waves is one of the parameters in videostroboscopy. Mucosal waves are the movement of the vocal cords from an inferior to a superior direction following the glottic cycle on the vertical axis. Changes in mucosal waves are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Vertical Level The vertical level is a parameter of the vocal cords on videostroboscopy that describes the difference in the height of the vocal cords that meet and are seen in the medial of the vocal cords. Changes in vertical level are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Supraglottic Activity The supraglottic activity is one of the parameters in videostroboscopy. Supraglottic activity describes a narrowing of the supraglottic structure wherein one of them is a collapsed arytenoid. Changes in supraglottic activity are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Non-vibrating Parts The non-vibrating parts is one of the parameters in videostroboscopy. The non-vibrating part is the part of the vocal cords that does not experience vibrations due to tissue rigidity. Assessment of this parameter is by dividing the right and left vocal cords into 10 regions each with an oval line. Changes in non-vibrating parts are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Free Edge Contours The free edge contours is one of the parameters in videostroboscopy. This parameter represents the free edge of the medial side of the vocal cords at maximal abduction. Changes in free edge contours are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Symmetrical Pattern This parameter assesses the symmetrical movement of the right and left vocal cords during oscillation using videostroboscopy. The results of the assessment on this parameter are symmetrical or asymmetrical. Changes in symmetrical pattern are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in Closure Phase The closure phase is a parameter that compares the amount of closure and opening of the vocal cords in one glottic cycle. Assessment is done by looking at a collection of pictures from videostroboscopy when the vocal cords oscillate. Changes in closure phase are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
Primary Changes in The Stability of The Vocal Cords The stability of the vocal cords is a parameter that measures the vibration and amplitude of the vocal cords that are oscillating in one glottic cycle Assessment of this parameter where done through videostroboscopy. Changes in the stability of the vocal cords are recorded and statistically analysed. Before injection, 1 week, 4 week, 8 week post-injection
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02244697 - The Yield of Laryngeal Ultrasound in the Evaluation of Stridor and Dysphonia in Children N/A
Recruiting NCT06227039 - Patient Augmented Reality and Vibratory Array Otorhinolaryngology Procedures N/A
Recruiting NCT04396912 - Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort
Completed NCT04458818 - A Novel Approach for Thyroplasty Type 1, With Prolene Mesh. A Prospective Study. N/A
Completed NCT00213616 - Bilateral Laryngeal Paralysis Reinnervation N/A
Completed NCT00382369 - Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis N/A
Completed NCT01824849 - Total Versus Partial Arytenoidectomy in Bilateral Vocal Fold Paralysis N/A
Completed NCT04315415 - A Histological Study Evaluating Silk Voice and Crosslinked Hyaluronic Acid N/A
Completed NCT00845442 - Dynamic Laryngeal Opening for Bilateral Vocal Fold Paralysis by an Implanted Stimulator N/A
Recruiting NCT00213863 - Implantation of Porous Titanium Prosthesis in Laryngeal Surgery Phase 2
Completed NCT04764604 - Evaluating the Feasibility of Acapella® Choice as a Dysphonia Treatment N/A
Recruiting NCT03634956 - Effect of IONM on Efficacy and Safety Using Sugammadex in Thyroid Surgery N/A
Recruiting NCT05542550 - Voice Rest and Injection Laryngoplasty N/A
Not yet recruiting NCT06078527 - Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort N/A